Publication

Clinical trials

1. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349:36-44.

2. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. 2004;65:1440-1448.

3. de Groot K, Rasmussen N, Bacon PA et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52:2461-2469.

4. Jayne DR, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180-2188.

5. de Groot K, Harper L, Jayne DR et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150:670-680.

6. Jones RB, Cohen Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211-220.

7. Hiemstra TF, Walsh M, Mahr A et al. Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Trial. JAMA. 2010

 

Database studies

8. Martinez Del Pero M, Walsh M, Luqmani R et al. Long-term damage to the ENT system in Wegener's granulomatosis. Eur Arch Otorhinolaryngol. 2010

9. Heijl C, Harper L, Flossmann O et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis. 2011;70:1415-1421.

10. Flossmann O, Berden A, de Groot K et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70:488-494.

11. Suppiah R, Hadden RD, Batra R et al. Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2011

12. Suppiah R, Judge A, Batra R et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken). 2011;63:588-596.

13. Walsh M, Flossmann O, Berden A et al. Risk factors for relapse of ANCA associated vasculitis. Arthritis Rheum. 2011

14. Walsh M, Mukhtyar C, Mahr A et al. Health related quality of life in patients with newly diagnosed anti-neutrophil cytoplasm antibody associated vasculitis. Arthritis Care Res (Hoboken). 2011

15: Heijl C, Harper L, Flossmann O, et al. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. Ann Rheum Dis. 2011;70:1415-21.

16: Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis. 2012;71:955-60.

17: Rasmussen N, Salmela A, Ekstrand A et al. Changes in proteinase 3 anti-neutrophil cytoplasm autoantibody levels in early systemic granulomatosis with polyangiitis (Wegener's) may reflect treatment rather than disease activity. Clin Exp Rheumatol. 2013;31:S38-44.

18: Pepper RJ, Chanouzas D, Tarzi R et al. Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2013;8:219-24.

19: Mahr A, Katsahian S, Varet H et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis. 2013;72:1003-10.

20: Walsh M, Casian A, Flossmann O et al. Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int. 2013;84:397-402.

21: Robson J, Doll H, Suppiah R et al. Damage in the ANCA-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2013.

 

Disease assessment

22. Bacon PA, Moots RJ, Exley A, Luqmani R, Rasmussen N. VITAL (Vasculitis Integrated Assessment Log) assessment of vasculitis. Clin Exp Rheumatol. 1995;13:275-278.

23. Flossmann O, Bacon P, de Groot K et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66:283-292.

24. Flossmann O, Bacon P, de Groot K et al. Development of comprehensive disease assessment in systemic vasculitis. Postgrad Med J. 2008;84:143-152.

25. Mukhtyar C, Flossmann O, Hellmich B et al. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis. 2008;67:1004-1010.

26. Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham Vasculitis Activity Score (Version 3). Ann Rheum Dis. 2008

27. Merkel PA, Cuthbertson DD, Hellmich B et al. Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis. 2009;68:103-106.

28. Seo P, Jayne D, Luqmani R, Merkel PA. Assessment of damage in vasculitis: expert ratings of damage. Rheumatology (Oxford). 2009

Renal Histopathology studies

29. Bajema IM, Hagen EC, Hansen BE et al. The renal histopathology in systemic vasculitis: an international survey study of inter- and intra-observer agreement. Nephrol Dial Transplant. 1996;11:1989-1995.

30. Bajema IM, Hagen EC, Hermans J et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int. 1999;56:1751-1758.

31. Bajema IM, Hagen EC, Ferrario F et al. Renal granulomas in systemic vasculitis. EC/BCR Project for ANCA-Assay Standardization. Clin Nephrol. 1997;48:16-21.

32. Hauer HA, Bajema IM, Hagen EC et al. Long-term renal injury in ANCA-associated vasculitis: an analysis of 31 patients with follow-up biopsies. Nephrol Dial Transplant. 2002;17:587-596.

33. Hauer HA, Bajema IM, van Houwelingen HC et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int. 2002;61:80-89.

34. Hauer HA, Bajema IM, Van Houwelingen HC et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002;62:1732-1742.

35. Vergunst CE, van Gurp E, Hagen EC et al. An index for renal outcome in ANCA-associated glomerulonephritis. Am J Kidney Dis. 2003;41:532-538.

36. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R et al. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol. 2006;17:2264-2274.

37. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R et al. Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2007;18:2189-2197.

38. Berden AE, Ferrario F, Hagen EC et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol. 2010;21:1628-1636.

39. Berden AE, Jones RB, Erasmus DD, Walsh M, Noel LH, Ferrario F, Waldherr R, Bruijn JA, Jayne DR, Bajema IM. Tubular Lesions Predict Renal Outcome in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis after Rituximab Therapy. J Am Soc Nephrol. 2011 Nov 17. [Epub ahead of print].

 

Serology studies

40. Rasmussen N, Wiik A, Hoier-Madsen M, Borregaard N, van der Woude F. Anti-neutrophil cytoplasm antibodies 1988. Lancet. 1988;1:706-707.

41. Hagen EC, Andrassy K, Chernok E et al. The value of indirect immunofluorescence and solid phase techniques for ANCA detection. A report on the first phase of an international cooperative study on the standardization of ANCA assays. EEC/BCR Group for ANCA Assay Standardization. J Immunol Methods. 1993;159:1-16.

42. Hagen EC. Development and standardization of solid-phase assays for the detection of antineutrophil cytoplasmic antibodies (ANCA) for clinical application: report of a large clinical evaluation study. Clin Exp Immunol. 1995;101 Suppl 1:29.

43. Hagen EC, Andrassy K, Csernok E et al. Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods. 1996;196:1-15.

44. Hagen EC, Daha MR, Hermans J et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int. 1998;53:743-753.

45. Savige J, Dimech W, Fritzler M et al. Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol. 2003;120:312-318.

46. Savige J, Gillis D, Benson E et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol. 1999;111:507-513.

 

Guideline statements

47. Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66:605-617.

48. Mukhtyar C, Boumpas D, Gordon C, Gross W, Jayne D, Luqmani R. Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus. Ann Rheum Dis. 2007;66:569-570.

49. Mukhtyar C, Guillevin L, Cid MC et al. EULAR Recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2008;68:310-317.

50. Mukhtyar C, Guillevin L, Cid MC et al. EULAR Recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2008;68:318-323.

51. Basu N, Watts R, Bajema I et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis. 2010

 

Reviews

52. Rasmussen N, Jayne D, Abramovicz D et al. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol. 1995;101.

53. Rasmussen N. Consensus therapeutic regimens for ANCA-associated systemic vasculitis. The European Community Systemic Vasculitis Study Group. Lancet. 1997;349:1029-1030.

54. Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc. 1997;72:737-747.

55. de Groot K. [Initial results of multicenter, randomized, controlled therapy studies for ANCA-associated vasculitis]. Z Rheumatol. 2003;62:116-117.

56. Tesar V, Rihova Z, Jancova E, Rysava R, Merta M. Current treatment strategies in ANCA-positive renal vasculitis-lessons from European randomized trials. Nephrol Dial Transplant. 2003;18 Suppl 5:v2-4.

57. de Groot K, Jayne D. What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides. Clin Nephrol. 2005;64:480-484.